Decentralized clinical trials are reshaping how pharmaceutical and biotech companies conduct research. Instead of requiring patients to visit physical trial sites, DCTs bring the trial to patients via telemedicine, home health visits, wearable devices, and remote monitoring.
The approach offers significant advantages. Patients participate from home, eliminating travel burden and expanding recruitment beyond major metropolitan areas. Sponsors accelerate enrollment, improve retention, and capture real-world data in patients’ actual living environments instead of artificial clinical settings.
The numbers validate this shift. The global decentralized clinical trials market is exploding from USD 9.39 billion in 2025 to a projected USD 21.06 billion by 2031, a 14.42% CAGR. The pandemic forced adoption, and regulatory agencies worldwide now accept DCT methodologies as standard practice.
But what nobody mentions is that decentralized doesn’t mean easier. It means different problems, often harder ones.
Here are the five biggest obstacles and how to actually fix them.
1. Patient Recruitment and Engagement
Removing location barriers exposes a harder challenge: communication barriers.
You’re not just recruiting patients, you’re recruiting patients who speak different languages, navigate different healthcare systems, and bring different levels of health literacy and digital competency. And you’re trying to engage them remotely without the relationship-building that happens naturally during traditional site visits.
Traditional recruitment materials fall apart here, since a consent form that works perfectly in English becomes incomprehensible when translated word-for-word into another language.
Keeping patients engaged remotely is also exponentially harder than in-person trials. Without regular face-to-face contact with trial staff, participants feel disconnected. That disconnect shows up quickly in your data through drops in adherence, spikes in dropout rates, and recruitment numbers that become meaningless.
The solution starts with localization, not translation.
Stop writing everything in English and translating later. That approach guarantees comprehension problems. Instead, design culturally relevant content for each market and choose examples that resonate locally.
While you’re at it, simplify onboarding. Every additional form, confusing instruction, and technical hurdle increases the risk of dropout. Test your enrollment process with actual patients from your target demographics to eliminate friction before launch.
But don’t stop at enrollment. Build ongoing engagement into your trial design. Regular check-ins, clear communication about what happens next, and responsive support in participants’ native languages keep patients connected. Patient retention in clinical trials improves dramatically when participants feel supported rather than abandoned after enrollment.
2. Regulatory Compliance Across Regions
Decentralized trials span multiple jurisdictions. Every jurisdiction has different regulatory requirements for informed consent, data privacy, remote monitoring, and adverse event reporting.
The regulatory landscape grows increasingly complex the more you look at it. The FDA allows certain DCT methodologies, whereas the EMA has different guidelines. Some regions require in-person consent witnessed by qualified personnel, while others accept electronic consent with digital signatures.
The solution requires regulatory expertise combined with flawless localization.
Start by getting the translation of regulatory documents right – protocols, informed consent forms, investigator brochures, and case report forms. Regulatory documents require precision, since a mistranslated exclusion criterion can compromise trial integrity and patient safety.
But accurate translation alone isn’t enough. You need to align with local regulatory requirements and work with regulatory experts in each target country who actually understand local DCT guidance.
The trick is maintaining consistency across markets while adapting to local requirements. Your core protocol should remain consistent, but implementation details should be adapted locally within regulatory constraints.
Professional clinical trial translation services that understand both regulatory requirements and linguistic nuances prevent disasters that derail trials.
3. Data Quality and Consistency
Traditional trials collect data in controlled clinical settings with trained staff ensuring accuracy. Decentralized trials collect data in patients’ homes using devices that participants manage themselves.
This makes data quality a variable rather than a constant. Imagine the individual errors across countries, languages, and patient populations that have just created nightmares.
The solution combines standardization with clarity.
Standardize data collection processes across all sites and languages first. Use the same devices, the same protocols, and then the same timing. Minimize variation to avoid creating confounding variables in your analysis. This baseline consistency makes the next steps possible.
It’s important to build quality control into the process, not just at the end. Apply rigorous validation checks in digital data capture systems, and flag inconsistent or out-of-range values immediately. Follow up with participants when the data looks questionable before it becomes part of your dataset.
4. Language Barriers and Communication Gaps
Decentralized trials multiply communication touchpoints while reducing face-to-face interaction, which naturally overcomes language barriers.
This creates a challenging dynamic, and it creates problems at every level.
Patients need to understand consent forms, protocol requirements, and device instructions. Whereas trial staff need to communicate across time zones and languages. If you multiply every one of those touchpoints by multiple languages across several countries, you’ll quickly realize that every communication gap creates risk.
Quick translation by non-professionals may seem cheaper until you factor in the actual costs: study delays, data quality issues, regulatory problems, and enrollment failures resulting from miscommunication.
The solution requires professional translation infrastructure across all trial communications.
Use professional translation for all key materials. This isn’t the place to cut costs by using machine translation or having bilingual staff do translations on the side. The risks are too high, and the downstream costs of errors are too expensive.
Beyond translation quality, ensure consistent terminology across all languages. Build glossaries that define exact translations for all key trial terms, and enforce them.
But don’t stop at documents; also provide multilingual support for patients and trial staff. When patients have questions, they need to speak with someone who speaks their language and understands the protocol.
5. Technology Access and Usability
Decentralized trials depend on technology, such as smartphones, tablets, wearables, and home monitoring devices. Not all patients have equal access to technology or the comfort of using it, and that’s a fundamental challenge.
The digital divide shows up in ways most sponsors don’t anticipate. For example, older patients may struggle with smartphone apps, whereas rural participants lack reliable internet connectivity.
The irony here is that designing your trial around technology that excludes significant patient populations defeats the entire purpose of decentralization. You’re just creating different barriers instead of removing them.
The solution requires inclusive design and comprehensive support.
Start with intuitive, user-friendly platforms that don’t assume a high level of technical proficiency. Make sure to back up your platform with clear, multilingual instructions and visual demonstrations.
Sometimes the smartest move is to provide devices rather than require patients to use their own. This ensures everyone has compatible technology and reduces barriers for participants who lack devices or reliable internet.
Finally, build offline functionality where possible. Design systems that work even with intermittent internet access, so technical infrastructure doesn’t become another exclusion criterion.
Get Decentralized Trials Right!
Decentralized trials have real benefits, but only when communication works across languages, cultures, and markets. The difference between DCT success and failure is the professional infrastructure that supports every patient interaction, regulatory submission, and data collection point.
At EC Innovations, we provide translation and localization services for global clinical trials. From informed consent forms to eDiary interfaces, we ensure every communication supports your objectives while meeting regulatory requirements. Contact us to discuss your decentralized clinical trial needs.
